Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN217 in Relapsed/Refractory Multiple Myeloma
DRKS00023656Phase 2Not yet recruiting
- Sponsor
- Harpoon Therapeutics
- Start
- Apr 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of HPN217 in multiple myeloma (MM), sponsored by Harpoon Therapeutics. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
HPN217
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on DRKS00023656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023656.